Belite Bio, Inc. ADR (BLTE) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Belite Bio, Inc. has appointed Dr. Hendrik P. N. Scholl, a world-renowned ophthalmologist, as their new Chief Medical Officer. Dr. Scholl’s extensive experience in retinal diseases, including his role in the largest Stargardt disease study, positions him to advance Belite Bio’s lead drug candidate, Tinlarebant, targeting macular degenerations. This strategic move aims to bolster the company’s commitment to developing treatments for eye conditions with high unmet medical needs.
For further insights into BLTE stock, check out TipRanks’ Stock Analysis page.